Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475162 · ClinicalTrials.gov registry record · Phase 1
Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01475162 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 14 participants.
The verdict
NCT01475162, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This trial designed to evaluate the toxicity and efficacy of tocilizumab in the treatment of steroid refractory acute graft versus host disease (GVHD).
Interventions
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-08-08 |
| Est. Completion | 2018-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475162
The ClinicalTrials.gov registry entry for NCT01475162 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tocilizumab is the first listed.
NCT01475162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01475162 about?
NCT01475162 is a clinical study titled "Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease". This trial designed to evaluate the toxicity and efficacy of tocilizumab in the treatment of steroid refractory acute graft versus host disease (GVHD).
What is the current status of trial NCT01475162?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-08-08. Estimated completion is 2018-09-29.
What interventions are being tested in trial NCT01475162?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT01475162?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.